Aldeyra is committed to developing safe and effective drugs for serious medical conditions.
A topical dermatological therapy is currently being developed by Aldeyra which is intended to facilitate removal of excess fatty aldehydes as a potential treatment for the itchy, dry, scaly skin disease (ichthyosis) in patients with SLS. Future clinical trials of ADX-102 may involve systemic administration as a potential treatment for the neurological aspects of the disease.
Noninfectious Anterior Uveitis
Noninfectious anterior uveitis is a rare, potentially blinding disease that may be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation in the front of the eye, pain, impaired vision, and photophobia.
Allergic conjunctivitis is a common allergic disease that is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, lid swelling and redness.
Succinic Semi-Aldehyde Dehydrogenase Deficiency
Succinic Semi-aldehyde Dehydrogenase Deficiency (SSADHD) is a rare disease caused by mutations in succinic semi-aldehyde dehydrogenase, leading to elevated levels of succinic semi-aldehyde that result in the formation of neurotoxic metabolites. SSADHD is characterized clinically by neurological compromise that includes cognitive and developmental delay, decreased muscle tone, and, in some cases, seizures. There is no FDA-approved therapy for SSADHD.